Aurora Cannabis has launched a new medical cannabis product. It is called “Black Jelly.” This happened on December 11, 2025. The launch is in Poland. This is a significant move for Aurora. It expands their offerings in Europe. Poland’s medical cannabis market is growing rapidly. Aurora’s new cultivar is “Black Jelly.” It is a proprietary strain. This means Aurora developed it. It is a high-potency product. This aligns with market trends. The product has a THC content of 27%. Its CBD content is less than 1%. This profile makes it potent.
Aurora grows this cannabis in Canada. Its facilities meet GACP and EU-GMP standards. These certifications are crucial. They ensure high quality. They are required for export to Europe. “Black Jelly” is a sativa. It comes from the “Alien Cake 3030 × T037” lineage. The flowers are dense. They have green and orange hues. The scent has notes of sweet black licorice. Fruity undertones are also present. This unique terpene profile is appealing. It is part of Aurora’s “Cannabis flos Aurora” brand.
Poland’s Medical Cannabis Market
Poland is a key European market. It is one of the fastest-growing. The market generated $5.3 million in 2023. It is projected to reach $27.4 million by 2030. The compound annual growth rate is 26.4%. Imports surged significantly. They rose from 300 kg in 2020 to over 11 tonnes by 2024. Pharmacy sales also grew. They reached a projected 7.8 tonnes in 2024. This shows strong patient demand. Poland is now Europe’s fourth-largest market. It is valued at €72 million in 2025. The market legalized medical cannabis in 2017. Aurora was an early entrant. They supplied their first shipment in 2018. This demonstrates their commitment to the region.
Aurora’s Strategic Approach
Aurora leverages its extensive experience. The company has over a decade in global medical markets. They focus on genetic breeding. They also emphasize cultivation excellence. Aurora’s EU-GMP certification is vital. It ensures product consistency. It meets international regulatory demands. This allows for easier market access. The company has multiple certified facilities. This bolsters their export capabilities. “Black Jelly” joins other Aurora products. Farm Gas and Sourdough are already available. This new launch strengthens Aurora’s portfolio. It meets patient needs for high-potency options.
Product Details and Patient Access
“Black Jelly” offers a specific cannabinoid profile. It is high in THC. This makes it suitable for experienced patients. It may help with mood and energy. Polish prescribers can access “Black Jelly.” Availability began on December 11, 2025. This provides new treatment tools. Doctors can use it for patient care. The expansion also involves necessary equipment for distribution. This news is significant for the trending cannabis sector.
Market Implications and Future Outlook
This launch signifies Aurora’s dedication. They aim to lead in international medical cannabis. Poland’s market presents opportunities. Despite regulatory shifts, it continues to grow. Aurora’s strategy includes innovation. They focus on proprietary cultivars. This differentiation is key. The company uses advanced breeding programs. They also employ premium hang-drying and curing techniques. This ensures product quality. The introduction of “Black Jelly” is timely. It meets a growing demand for superior products. This news is important industry news. It highlights the evolving European cannabis landscape. Aurora remains a trusted partner. They support Poland’s medical cannabis ecosystem. The availability of such products offers new therapeutic possibilities. It also fuels market growth. Tools and equipment are essential for this supply chain. The market continues to adapt. New trends are emerging. Aurora is well-positioned for future developments. This contributes to broader patient access. Aurora’s global infrastructure is a major asset. They are set to benefit from market expansion. This collaboration helps advance patient care. Aurora’s commitment remains strong. They focus on high-quality cannabis.
